Vivos Therapeutics, Inc. / Fundamentals
Income statement
- Net revenue
€12.35M - Cost of goods sold
€5.44M - Gross profit
€6.91M - SG&A expenses
€18.46M - R&D expenses
€85.80K - EBITDA
-€11.52M - D&A
€663.23K - EBIT
-€11.80M - Interest expenses
€0.00 - EBT
-€12.29M - Tax expenses
-€1.23M - Net income
-€12.29M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€2.15M - Changes in working capital
€1.12M - Operating cash flow
-€12.37M - Capex
€622.05K - Other investing cash flow
-€592.02K - Net investing cash flow
-€5.48M - Total cash dividends paid
€0.00 - Issuance of common stock
-€4.90M - Debt repayment
€8.27M - Other financing cash flow
€2.87M - Net financing cash flow
€15.70M - Foreign exchange effects
€0.00 - Net change in cash
-€2.15M - Cash at end of period
€3.78M - Free cash flow
-€11.75M
Balance sheet
- Cash and cash equivalents
€3.78M - Cash and short-term investments
€3.78M - Total receivables
€1.40M - Inventory
€0.00 - Other current assets
€596.31K - Total current assets
€5.77M - Property, plant & equipment
€7.18M - Goodwill
€7.25M - Intangible assets
€1.91M - Long-term investments
€0.00 - Other non-current assets
€218.79K - Total non-current assets
€16.56M - Total assets
€22.34M - Accounts payable
€1.51M - Short-term debt
€743.03K - Other current liabilities
€2.85M - Total current liabilities
€5.51M - Long-term debt
€9.19M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€3.69M - Total non-current liabilities
€12.89M - Total liabilities
€18.40M - Common stock
€0.00 - Retained earnings
-€97.01M - Other equity
€0.00 - Total equity
€3.93M - Total liabilities and shareholders' equity
€22.34M
Company information
- Market capitalization
€16.48M - Employees
109 - Enterprise Value
€12.13M
Company ratios
- Gross margin
-
55.9% Much better than peer group: -147.9% - EBITDA margin
-
-93.3% Much better than peer group: -37,224.0% - EBIT margin
-
-95.5% Much better than peer group: -37,357.5% - EBT margin
-
-99.5% Much better than peer group: -37,374.4% - Net margin
-
-99.5% Much better than peer group: -37,326.3% - ROE
-
-312.5% Much worse than peer group: -95.4% - ROA
-
-55.0% Much better than peer group: -16,192.6% - Asset turnover
-
55.3% Much better than peer group: 17.1% - FCF margin
-
-105.2% Much better than peer group: -27,931.3% - FCF yield
-78.8% - Efficiency ratio
193.3% - Net sales per employee
-
€113.30K - Net income per employee
-
-€112.72K